BRAF and carcinoma: However, of the 30 cases that were classified as BSRTC I-III but proved to be carcinomas by histopathology, 27 were positive for BRAFV600E mutation, indicating the vital value of BRAF mutation analysis in lesions with BSRTC I-III.